crizanlizumab
Selected indexed studies
- Crizanlizumab. (, 2006) [PMID:32401467]
- Crizanlizumab: First Approval. (Drugs, 2020) [PMID:31933169]
- Crizanlizumab. (, 2012) [PMID:34406730]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Crizanlizumab. (2006) pubmed
- Crizanlizumab: First Approval. (2020) pubmed
- Crizanlizumab. (2012) pubmed
- Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. (2017) pubmed
- Crizanlizumab in sickle cell disease. (2023) pubmed
- Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial. (2025) pubmed
- Crizanlizumab. (2023) pubmed
- Sickle Cell Disease: A Review. (2022) pubmed
- Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease. (2021) pubmed
- Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis. (2020) pubmed